Jason S. Starr

462 total citations
37 papers, 267 citations indexed

About

Jason S. Starr is a scholar working on Oncology, Epidemiology and Cancer Research. According to data from OpenAlex, Jason S. Starr has authored 37 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 12 papers in Epidemiology and 12 papers in Cancer Research. Recurrent topics in Jason S. Starr's work include Pancreatic and Hepatic Oncology Research (13 papers), Neuroendocrine Tumor Research Advances (12 papers) and Cancer Genomics and Diagnostics (12 papers). Jason S. Starr is often cited by papers focused on Pancreatic and Hepatic Oncology Research (13 papers), Neuroendocrine Tumor Research Advances (12 papers) and Cancer Genomics and Diagnostics (12 papers). Jason S. Starr collaborates with scholars based in United States, Netherlands and Brazil. Jason S. Starr's co-authors include Kabir Mody, Mohamad Bassam Sonbol, Pashtoon Murtaza Kasi, Sakti Chakrabarti, Kelsey Poorman, Benjamin A. Weinberg, Mohamed E. Salem, Michelle Saul, Anthony F. Shields and Ari M. Vanderwalde and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jason S. Starr

27 papers receiving 266 citations

Peers

Countries citing papers authored by Jason S. Starr

Since Specialization

Citations

This map shows the geographic impact of Jason S. Starr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason S. Starr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason S. Starr more than expected).

Fields of papers citing papers by Jason S. Starr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason S. Starr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason S. Starr. The network helps show where Jason S. Starr may publish in the future.

Co-authorship network of co-authors of Jason S. Starr

This figure shows the co-authorship network connecting the top 25 collaborators of Jason S. Starr. A scholar is included among the top collaborators of Jason S. Starr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason S. Starr. Jason S. Starr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis 2025 ·The Oncologist ·(unknown), Syed Arsalan Ahmed Naqvi, (unknown), (unknown), (unknown), (unknown), (unknown), Zhaohui Jin, Harry H. Yoon, Pedro Luiz Serrano Usón, Jason S. Starr, Daniel H. Ahn, (unknown), Irbaz Bin Riaz, Mohamad Bassam Sonbol	2
2	Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study 2025 ·JCO Precision Oncology ·(unknown), Bobak Seddighzadeh, (unknown), (unknown), Rish K. Pai, Christopher Hartley, Jason S. Starr, Tanios Bekaii‐Saab, Þorvarður R. Hálfdánarson, Mohamad Bassam Sonbol	0
3	Immune Checkpoint Inhibitors for Mismatch Repair–Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic 2025 ·JCO Precision Oncology ·(unknown), (unknown), Rish K. Pai, (unknown), (unknown), Mitesh J. Borad, (unknown), (unknown), Hao Xie, Robert R. McWilliams, Nguyen H. Tran, Travis E. Grotz, Fang‐Shu Ou, Nabil Wasif, Jason S. Starr, Tanios Bekaii‐Saab, Christina Wu, Harry H. Yoon, Daniel H. Ahn, Mohamad Bassam Sonbol	0
4	The impact of peptide receptor radionucleotide therapy with Lutetium-177 DOTATATE on cardiac metastases in neuroendocrine tumors 2024 ·European Heart Journal ·Isabel G. Scalia, (unknown), (unknown), M.L. González Pereyra, Yan Wang, Tanios Bekaii‐Saab, Ming Yang, Heidi M. Connolly, Patricia A. Pellikka, Sandra M. Herrmann, (unknown), Jason S. Starr, (unknown), Reza Arsanjani, Christian Ayoub	0
5	Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study 2024 ·JCO Precision Oncology ·Yael Kusne, Terra L. Lasho, Christy M. Finke, (unknown), (unknown), Timothy J. Hobday, Jason S. Starr, Tanios Bekaii‐Saab, Þorvarður R. Hálfdánarson, Mrinal M. Patnaik, Fang‐Shu Ou, Mohamad Bassam Sonbol	2
6	Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma 2024 ·JCO Oncology Practice ·Derk C.F. Klatte, Jason S. Starr, (unknown), (unknown), Jeanin E. van Hooft, Monique E. van Leerdam, Thomas P. Potjer, (unknown), Douglas L. Riegert‐Johnson, Michael B. Wallace, Yan Bi	7
7	Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), Ephraim E. Parent, Jason R. Young, Geoffrey B. Johnson, A. Tuba Kendi, Þorvarður R. Hálfdánarson, Jason S. Starr	0
8	Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial 2024 ·Journal of Clinical Oncology ·Daniel H. Ahn, Maya Ridinger, Timothy Lewis Cannon, (unknown), Jason S. Starr, Joleen M. Hubbard, Anup Kasi, Afsaneh Barzi, Errin Samuëlsz, Anju Karki, Ramanand A. Subramanian, (unknown), Roy Kim, (unknown), Peter J.P. Croucher, Tod Smeal, Fairooz F. Kabbinavar, Heinz‐Josef Lenz	11
9	Lutetium-177 DOTATATE Therapy and Cardiac Outcomes in Patients With Neuroendocrine Tumor and Cardiac Metastases 2024 ·JACC CardioOncology ·Isabel G. Scalia, (unknown), Juan Farina, (unknown), Yuxiang Wang, (unknown), (unknown), Heidi M. Connolly, Patricia A. Pellikka, Joerg Herrmann, Þorvarður R. Hálfdánarson, Jason S. Starr, Sushil Allen Luis, (unknown), Chadi Ayoub	1
10	Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms 2023 ·Best Practice & Research Clinical Endocrinology & Metabolism ·(unknown), Mohamad Bassam Sonbol, Þorvarður R. Hálfdánarson, Jason S. Starr	5
11	Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience 2023 ·JCO Precision Oncology ·(unknown), Aakash Desai, Hani M. Babiker, Mohamad Bassam Sonbol, Sakti Chakrabarti, Amit Mahipal, Robert R. McWilliams, Wen Wee, Tanios Bekaii‐Saab, John Stauffer, Jason S. Starr	30
12	Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes 2023 ·JCO Precision Oncology ·Pashtoon Murtaza Kasi, (unknown), Jiemin Liao, Jason S. Starr, Pedro C. Barata, Samuel J. Klempner, David R. Gandara, Ardaman Shergill, Luciana Madeira da Silva, Caroline Weipert, Nicole Zhang, Christopher R. Pretz, Aaron Hardin, Lesli A. Kiedrowski, Justin I. Odegaard	8
13	Characterizing the genomic landscape of POLE/POLD1-mutated colorectal adenocarcinoma. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), Jeremy Jones, Joleen M. Hubbard, Tanios Bekaii‐Saab, Melissa C. Stoppler, Jason S. Starr	0
14	Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden 2023 ·Journal of Nuclear Medicine ·(unknown), (unknown), Ephraim E. Parent, Akash Sharma, (unknown), (unknown), A. Tuba Kendi, Geoffrey B. Johnson, Mohamad Bassam Sonbol, Timothy J. Hobday, Þorvarður R. Hálfdánarson, Jason S. Starr	4
15	Efficacy of first‐line checkpoint inhibitors in combination with chemotherapy in high‐grade extrapulmonary metastatic neuroendocrine carcinomas 2023 ·Journal of Neuroendocrinology ·Jennifer Gile, Patrick W. McGarrah, Konstantinos Leventakos, Mohamad Bassam Sonbol, Jason S. Starr, (unknown), Timothy J. Hobday, Þorvarður R. Hálfdánarson	1
16	Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment 2023 ·Current Oncology Reports ·Nikolaos Andreatos, Patrick W. McGarrah, Mohamad Bassam Sonbol, Jason S. Starr, Jaume Capdevila, Halfdan Sørbye, Þorvarður R. Hálfdánarson	0
17	Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer 2022 ·Journal for ImmunoTherapy of Cancer ·Sakti Chakrabarti, (unknown), Jason S. Starr, (unknown), Ardaman Shergill, (unknown), Regina Resta, Stephanie A. Wagner, (unknown), Pashtoon Murtaza Kasi	38
18	Albumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing Yttrium-90 radioembolization using resin microspheres 2020 ·Journal of Gastrointestinal Oncology ·Antoine Azar, Zlatko Devcic, Ricardo Paz‐Fumagalli, (unknown), J. Mark McKinney, G. Frey, Andrew R. Lewis, Charles Ritchie, Jason S. Starr, Kabir Mody, Beau B. Toskich	6
19	Two Cases of Rare Pancreatic Malignancies 2019 ·SHILAP Revista de lepidopterología ·(unknown), Hiral D. Parekh, (unknown), Michael Feely, Thomas J. George, Jason S. Starr	4
20	Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers 2019 ·Journal of Gastrointestinal Oncology ·Kabir Mody, Jason S. Starr, Michelle Saul, Kelsey Poorman, Benjamin A. Weinberg, Mohamed E. Salem, Ari M. Vanderwalde, Anthony F. Shields	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact